Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
Subscribe To Our Newsletter & Stay Updated
